KAYS
Price
$0.04
Change
-$0.00 (-0.00%)
Updated
Nov 18 closing price
Capitalization
26.28M
Intraday BUY SELL Signals
KMDA
Price
$6.95
Change
+$0.11 (+1.61%)
Updated
Nov 19, 04:59 PM (EDT)
Capitalization
398.21M
119 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

KAYS vs KMDA

Header iconKAYS vs KMDA Comparison
Open Charts KAYS vs KMDABanner chart's image
Kaya Holdings
Price$0.04
Change-$0.00 (-0.00%)
Volume$1.36K
Capitalization26.28M
Kamada
Price$6.95
Change+$0.11 (+1.61%)
Volume$400
Capitalization398.21M
KAYS vs KMDA Comparison Chart in %
KAYS
Daily Signal:
Gain/Loss:
KMDA
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
KAYS vs. KMDA commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KAYS is a Hold and KMDA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (KAYS: $0.04 vs. KMDA: $6.81)
Brand notoriety: KAYS and KMDA are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: KAYS: 7% vs. KMDA: 56%
Market capitalization -- KAYS: $19.85M vs. KMDA: $407.1M
KAYS [@Pharmaceuticals: Generic] is valued at $19.85M. KMDA’s [@Pharmaceuticals: Generic] market capitalization is $407.1M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.12B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KAYS’s FA Score shows that 1 FA rating(s) are green whileKMDA’s FA Score has 0 green FA rating(s).

  • KAYS’s FA Score: 1 green, 4 red.
  • KMDA’s FA Score: 0 green, 5 red.
According to our system of comparison, KAYS is a better buy in the long-term than KMDA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KAYS’s TA Score shows that 4 TA indicator(s) are bullish while KMDA’s TA Score has 4 bullish TA indicator(s).

  • KAYS’s TA Score: 4 bullish, 5 bearish.
  • KMDA’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, KAYS is a better buy in the short-term than KMDA.

Price Growth

KAYS (@Pharmaceuticals: Generic) experienced а -4.00% price change this week, while KMDA (@Pharmaceuticals: Generic) price change was -3.50% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -3.77%. For the same industry, the average monthly price growth was -6.55%, and the average quarterly price growth was +28.28%.

Reported Earning Dates

KMDA is expected to report earnings on Mar 18, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-3.77% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KMDA($398M) has a higher market cap than KAYS($26.3M). KMDA has higher P/E ratio than KAYS: KMDA (19.54) vs KAYS (3.30). KAYS YTD gains are higher at: 37.143 vs. KMDA (15.077). KMDA has higher annual earnings (EBITDA): 34.2M vs. KAYS (-4.55M). KMDA has more cash in the bank: 66M vs. KAYS (48.1K). KAYS has less debt than KMDA: KAYS (9.36M) vs KMDA (11.4M). KMDA has higher revenues than KAYS: KMDA (170M) vs KAYS (24.3K).
KAYSKMDAKAYS / KMDA
Capitalization26.3M398M7%
EBITDA-4.55M34.2M-13%
Gain YTD37.14315.077246%
P/E Ratio3.3019.5417%
Revenue24.3K170M0%
Total Cash48.1K66M0%
Total Debt9.36M11.4M82%
FUNDAMENTALS RATINGS
KAYS vs KMDA: Fundamental Ratings
KAYS
KMDA
OUTLOOK RATING
1..100
154
VALUATION
overvalued / fair valued / undervalued
1..100
55
Fair valued
72
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10075
PRICE GROWTH RATING
1..100
3754
P/E GROWTH RATING
1..100
155
SEASONALITY SCORE
1..100
9050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KAYS's Valuation (55) in the null industry is in the same range as KMDA (72) in the Biotechnology industry. This means that KAYS’s stock grew similarly to KMDA’s over the last 12 months.

KAYS's Profit vs Risk Rating (100) in the null industry is in the same range as KMDA (100) in the Biotechnology industry. This means that KAYS’s stock grew similarly to KMDA’s over the last 12 months.

KMDA's SMR Rating (75) in the Biotechnology industry is in the same range as KAYS (100) in the null industry. This means that KMDA’s stock grew similarly to KAYS’s over the last 12 months.

KAYS's Price Growth Rating (37) in the null industry is in the same range as KMDA (54) in the Biotechnology industry. This means that KAYS’s stock grew similarly to KMDA’s over the last 12 months.

KAYS's P/E Growth Rating (1) in the null industry is somewhat better than the same rating for KMDA (55) in the Biotechnology industry. This means that KAYS’s stock grew somewhat faster than KMDA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KAYSKMDA
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
72%
Momentum
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
59%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
66%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
66%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bullish Trend 2 days ago
68%
Advances
ODDS (%)
Bullish Trend 14 days ago
70%
Bullish Trend 8 days ago
64%
Declines
ODDS (%)
Bearish Trend 10 days ago
78%
Bearish Trend 2 days ago
65%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
68%
Aroon
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 3 days ago
69%
View a ticker or compare two or three
Interact to see
Advertisement
KAYS
Daily Signal:
Gain/Loss:
KMDA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FGSAX61.940.07
+0.11%
Federated Hermes MDT Mid Cap Growth A
RYCCX485.39N/A
N/A
Rydex NASDAQ-100® 2x Strategy C
AFCNX18.55N/A
N/A
American Century Focused Intl Gr Inv
PETGX13.75N/A
N/A
Gabelli Pet Parents'™ A
BRWJX28.51-0.32
-1.11%
MFS Blended Research Growth Eq I

KAYS and

Correlation & Price change

A.I.dvisor tells us that KAYS and KMDA have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that KAYS and KMDA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KAYS
1D Price
Change %
KAYS100%
N/A
KMDA - KAYS
21%
Poorly correlated
-0.39%
UPC - KAYS
8%
Poorly correlated
-2.47%
SHIEF - KAYS
4%
Poorly correlated
N/A
TRUFF - KAYS
4%
Poorly correlated
-10.26%
IMCC - KAYS
3%
Poorly correlated
+34.20%
More

KMDA and

Correlation & Price change

A.I.dvisor tells us that KMDA and OGI have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that KMDA and OGI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KMDA
1D Price
Change %
KMDA100%
-0.39%
OGI - KMDA
29%
Poorly correlated
+5.03%
SGIOY - KMDA
27%
Poorly correlated
+1.17%
SIGA - KMDA
26%
Poorly correlated
+1.19%
CRDL - KMDA
25%
Poorly correlated
+5.10%
TEVA - KMDA
24%
Poorly correlated
+1.02%
More